Fig. 4: Adjusted overall survival curves. | British Journal of Cancer

Fig. 4: Adjusted overall survival curves.

From: Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial

Fig. 4

a intent-to-use 5-FU, b intent-to-use S-1, c baseline sum of the diameter of target lesions ≥60 mm, and d baseline sum of the diameter of target lesions <60 mm. 5-FU 5-fluorouracil, BEV bevacizumab, CI confidence interval, FOLFIRI 5-FU, leucovorin, and irinotecan, FP fluoropyrimidine, FTD/TPI trifluridine/tipiracil, HR hazard ratio, IRI irinotecan, NE not estimable. aAdjusted based on stratification factors.

Back to article page